Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Royal Marsden Hospital, Sutton, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:Sutton
Treatments:ChemotherapyHospital:Royal Marsden Hospital
Drugs:Journal:Link
Date:May 2012

Description:

Patients:
This phase 2 study involved 108 metastatic castration-resistant prostate cancer patients with a median age of 71 years.

Treatment:
Patients were treated with the chemotherapy agent eribulin mesylate.

Toxicities:
The most severe toxicities were of grade 4 and included febrile neutropenia and leukopenia. Grade 3 diarrhea and fatigue were also reported.

Results:
The median overall survival was 18.6 months.

Support:
This study was supported by Eisai Inc., makers of eribulin mesylate (brand name: Halaven).

Correspondence: Dr. J. S. de Bono; email: [email protected]



Back